📰 Jon Johnsson News
Page 2 - Jon Johnsson News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Jon Johnsson. Real-time updates on events, politics, business and more.
December 15, 2021
/PRNewswire/ -- The board of directors of Karo Pharma Aktiebolag (publ) (the "Company" or "Karo") has resolved to initiate a process to have the Companys...
December 15, 2021
HUDDINGE, Sweden, Dec. 15, 2021 /PRNewswire/ -- The board of directors of Karo Pharma Aktiebolag (publ) (the "Company" or "Karo") has resolved to initiate a process to have the Company's shares
October 28, 2021
HUDDINGE, Sweden, Oct. 28, 2021 /PRNewswire/ -- July - September Revenues amounted to MSEK 738.5 (679.1), corresponding to an increase of +9% for the period. The organic growth[1] during
May 6, 2021
Karo Pharma to sell its treasury shares HUDDINGE, Sweden, May 6, 2021 /PRNewswire/ -- Karo Pharma ("Karo") pursues a growth strategy, which combines geographical expansion with an active acquisition strategy. To execute on this strategy, Karo needs capital and a strong financial position. The treasury shares represent an unutilized resource in the company and a sale of the shares enhances Karos financial flexibility. On October 30, 2020 Karo communicated its intentions to sell its treasury shar...
April 28, 2021
Karo Pharma resolves on sale of own shares HUDDINGE, Sweden, April 28, 2021 /PRNewswire/ -- Under the the authorization from the 2021 Annual General Meeting, the Board of Directors has resolved to sell up to 1,768,000 own shares to expand the companys financial flexibility. The sale of own shares shall be effected - on one or several occasions before the 2022 Annual General Meeting, where a new mandate should be requested if necessary - on Nasdaq Stockholm at a price within the effective regist...
April 21, 2021
Interim report Q1 2021 Revenues amounted to MSEK 713.0 (793.6), corresponding to a decrease of -10% for the period. Revenues amounted to MSEK 713.0 ( 793.6), corresponding to a decrease of -10% for the period. The organic growth* during the first quarter was -16%. The currency impact in the quarter was -1% while the acquisitions of the product portfolios Proct from Leo Pharma and Pevaryl from Johnson & Johnson generated growth of +7%. EBIT (Operating Profit) amounted to MSEK 128.1 (104.1), ...